HC Wainwright & Co. Reiterates Buy on Tarsus Pharmaceuticals, Maintains $88 Price Target
Benzinga Newsdesk 6 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.
HC Wainwright & Co. analyst Matthew Caufield reiterates Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and maintains $88 price target.